EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
Business Wire India New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be presented, with nemolizumab demonstrating a continuous improvement in clinically meaningful…